Evidence map›Paper›PMID 27856749›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.

Yu-Ling Lin, Nu-Man Tsai, Cheng-Hao Hsieh, Shu-Yi Ho, Jung Chang, Hsin-Yi Wu, Ming-Hua Hsu, Chia-Ching Chang, Kuang-Wen Liao, Tiffany L B Jackson and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. B cells in tumor metastasis: friend or foe?International journal of biological sciences · 2023
    Review
  2. Review
  3. Article
  4. Leukotrienes in Tumor-Associated Inflammation.Frontiers in pharmacology · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Yu-Ling LinDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China.
Nu-Man TsaiSchool of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, 40201, Taiwan, Republic of China.
Cheng-Hao HsiehDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China.
Shu-Yi HoDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China.
Jung ChangDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China.
Hsin-Yi WuInstitute of Molecular Medicine and Bioengineering, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China.
Ming-Hua HsuNuclear Science & Technology Development Center, National Tsing Hua University, Hsinchu, 30013, Taiwan, Republic of China.
Chia-Ching ChangDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China.
Kuang-Wen LiaoDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China; rhuang@jhu.edu liaonms@mail.nctu.edu.tw.
Tiffany L B JacksonDepartment of Biology, Johns Hopkins University, Baltimore, MD 21218-2685.
David E MoldDepartment of Biology, Johns Hopkins University, Baltimore, MD 21218-2685.
Ru Chih C HuangDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30068, Taiwan, Republic of China; rhuang@jhu.edu liaonms@mail.nctu.edu.tw.
National Yang Ming Chiao Tung University · TWJohns Hopkins University · USChung Shan Medical University · TWNational Tsing Hua University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer progression is associated with the development of antitumor autoantibodies in patients' sera. Although passive treatment with antitumor antibodies has exhibited remarkable therapeutic efficacy, inhibitory effects on tumor progression by endogenous antitumor autoantibodies (EAAs) have been limited. In this study, we show that P

Indexed as

Signal TransductionActivinsAnimalsAntibodies, NeoplasmAntineoplastic AgentsAutoantibodiesB-Cell Activating FactorB-LymphocytesCell Line, TumorCell ProliferationColorectal NeoplasmsDose-Response Relationship, DrugDrug Screening Assays, AntitumorEndoplasmic Reticulum Chaperone BiPEpoxide HydrolasesFemale2,3-dimethyl-1,4-bis(3,4-(3-(piperdino)ethoxyphenyl))butaneactivin AActivinsAntibodies, NeoplasmAntineoplastic AgentsAutoantibodiesB-Cell Activating FactorEndoplasmic Reticulum Chaperone BiPEpoxide HydrolasesHspa5 protein, mouseImmunologic Factorsleukotriene A4 hydrolasePhenyl EthersPiperidinesTnfsf13b protein, mouseB-cell proliferationcancer immunotherapycolorectal cancerendogenous antitumor autoantibodyP4N

Identifiers

PMID27856749
PMCPMC5137775
OpenAlexW2551976688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.